Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder And Post-Traumatic Stress Disorder At The Society Of Toxicology 2025 Annual Meeting And ToxExpo
Alzamend Neuro将在2025年毒理学会年会上和ToxExpo上介绍AL001的药代动力学非临床数据更新，AL001是一种锂水杨酸盐/L-脯氨酸共晶，可能成为双相障碍类型1、阿尔茨海默病、重度抑郁障碍和创伤后应激障碍的有益锂节省治疗。
Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder
演讲主题是AL001的药代动力学，AL001是一种锂水杨酸盐/L-脯氨酸共晶，可能成为双相障碍类型1、阿尔茨海默病、重度抑郁障碍和创伤后应激障碍的有益锂节省治疗。
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Society of Toxicology ("SOT") Annual Meeting and ToxExpo, being held from March 16-20, 2025, in Orlando, Florida.
Alzamend Neuro, Inc.（纳斯达克：ALZN）（"Alzamend"），是一家临床阶段生物制药公司，专注于开发治疗阿尔茨海默病（"阿尔茨海默病"）、双相障碍（"BD"）、重度抑郁障碍（"MDD"）和创伤后应激障碍（"PTSD"）的新产品，今天宣布将在2025年3月16日至20日在佛罗里达州奥兰多举行的毒理学会（"SOT"）年会上和ToxExpo上进行海报展示。
